| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/25/2003 | USRE38009 A nutritional supplement, comprising a 3R-3'R stereoisomer of zeaxanthin in a digestible capsule or tablet designed and sized for human ingestion, wherein the 3R-3'R stereoisomer of zeaxanthin constitutes at least about 90 percent of all |
| 02/25/2003 | US6525220 Intermediates for the synthesis of benzimidazole derivatives and a process for the preparation thereof |
| 02/25/2003 | US6525215 HIV protease inhibitors |
| 02/25/2003 | US6525214 Contacting 2-(4-isobutylphenyl)propionic acid of high enantiomorph purity with sodium base; salt formation to form sodium ibuprofen; analgesics, antipyretics, antiinflammatory agents |
| 02/25/2003 | US6525207 Process for preparing epoxy compounds, aromatic compositions containing the same |
| 02/25/2003 | US6525206 Compounds with high monoamine transporter affinity |
| 02/25/2003 | US6525202 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 02/25/2003 | US6525199 Ring coupling, reduction and deprotecting; synthesis of compounds for alleviation and treatment of symptoms due to ischemic diseases |
| 02/25/2003 | US6525196 5HT1 antagonists for antidepressant therapy |
| 02/25/2003 | US6525193 Aminoaryl oxazolidinone N-oxides |
| 02/25/2003 | US6525184 Self-regulated apoptosis of inflammatory cells |
| 02/25/2003 | US6525100 Composition and method for treating peyronie's disease and related fibrotic tissue disorders |
| 02/25/2003 | US6525098 Treatment of inflammation, rheumatic, arthritic conditions; improved hydrolysis and solubility; reduced propensity to cause stomach irritation; analgesics and antipyretics |
| 02/25/2003 | US6525097 Method of treating a cancerous condition by enhancing the effectiveness of the human immune system |
| 02/25/2003 | US6525096 4-amino-3-(2-methylpropyl)butanolc acid; central nervous system disorders such as epilepsy, Huntington's chorea, cerebral ischernia, Parkinson's disease, tardive dyskinesia, and spasticity |
| 02/25/2003 | US6525095 Combined with a protein feed for ruminants to reduce insulin insensitivity and increase body weight |
| 02/25/2003 | US6525094 Method of treating hair loss using diphenylether derivatives |
| 02/25/2003 | US6525093 Compounds to treat diabetes and associated conditions |
| 02/25/2003 | US6525090 Methods of treating mental diseases, inflammation and pain |
| 02/25/2003 | US6525089 Pharmaceutical composition containing decursin |
| 02/25/2003 | US6525087 Use of known agonists of the central cannabinoid receptor CB1 |
| 02/25/2003 | US6525084 Granulating a mixture containing an active ingredient and a carrier in a high shear mixing means with temperature regulating means for keeping the temperature below about 40 degrees C. in the mixture during granulation |
| 02/25/2003 | US6525083 Antidiabetic agents, antilipemic agents, anticholesterol agents |
| 02/25/2003 | US6525080 Thiazoline acid derivatives |
| 02/25/2003 | US6525079 Antiparasitic compounds such as 4-(2,2-dibromocyclopropyl)-1-(2,6-dichloro-4-trifluoromethylphenyl)-1,2,3 -triazole |
| 02/25/2003 | US6525078 4-Methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinyl-methyl)-1,3-benzenedicarboxamide; vascular diseases |
| 02/25/2003 | US6525077 Cyanoguanidine prodrugs |
| 02/25/2003 | US6525075 Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene |
| 02/25/2003 | US6525073 Prevention or treatment of insomnia with a neurokinin-1 receptor antagonist |
| 02/25/2003 | US6525072 Prevention and treatment of cellular disorders such as cancer |
| 02/25/2003 | US6525071 Compositions and methods for the treatment and prevention of bovine mastitis |
| 02/25/2003 | US6525070 Bipiperidine derivatives as modulators of CCR3 activity and as H1 antagonists |
| 02/25/2003 | US6525068 Hydronaphtalene compounds, prepared by a rhodium catalyzed ring opening reaction in the presence of phosphine ligand |
| 02/25/2003 | US6525067 Substituted heterocyclic derivatives |
| 02/25/2003 | US6525066 4-oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure |
| 02/25/2003 | US6525063 3,7-dimethyl-1,5-diazaanthraquinone for example |
| 02/25/2003 | US6525062 Method of treating pain using nalbuphine and opioid antagonists |
| 02/25/2003 | US6525060 Triazolo(4,5-d)pyrimidine compounds |
| 02/25/2003 | US6525059 Substituted pyrazoles as p38 kinase inhibitors |
| 02/25/2003 | US6525058 1-ethyl methylester 4-((3- (p-(carboxyamidino)phenyl) -2-oxo-5-oxazolidinyl)methyl)-1-piperazineacetate; Gantofiban; antagonistic action to Glycoprotein GPIIb/IIIa receptor; oily base; gantofiban citrate |
| 02/25/2003 | US6525057 Sustained release ranolazine formulations |
| 02/25/2003 | US6525056 Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders |
| 02/25/2003 | US6525055 Allergic and inflammatory pathologies such as, for example, emphysema, chronic bronchitis, asthma and allergic rhinitis. |
| 02/25/2003 | US6525054 Cyanoiminoquinoxaline derivatives |
| 02/25/2003 | US6525053 2-Benzyl-5-(4-methylsulfonylphenyl)-6-(4-fluorophenyl)-3(2H) -pyridazinone; cyclooxygenase (COX) inhibitors pain, fever, inflammation, rheumatoid arthritis, osteoarthritis; minimizes GI and renal side-effects |
| 02/25/2003 | US6525052 Compounds useful as reversible inhibitors of cysteine proteases |
| 02/25/2003 | US6525051 For treating cytokine-induced hypotension, inflammatory bowel disease, cerebral ischemia, arthritis, adult respiratory distress syndrome, asthma |
| 02/25/2003 | US6525049 Pyrroloquinolones as antiviral agents |
| 02/25/2003 | US6525048 Aminomethylphenoxymethyl/benzisoxazole substituted azabicyclic compounds; depression, generalized anxiety disorder, obesity, migraine; 2-(5-Fluoro-benzo(d)isoxazol-3-y)-7-(3-morpholin-4-ylmethylphenoxymethyl) -octahydro-pyrido(1,2-a)pyrazine; |
| 02/25/2003 | US6525047 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair |
| 02/25/2003 | US6525045 Positive allosteric AMPA receptor modulators |
| 02/25/2003 | US6525044 Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. |
| 02/25/2003 | US6525043 Bicyclic or tricyclic ketones, oximes, amine oxides or amines are used as calcium or potassium channel modulators |
| 02/25/2003 | US6525041 Low molecular weight mimics of superoxide dismutase; inflammatory disorders, ischemic/reperfusion injury, stroke, atherosclerosis, and all other conditions of oxidant- induced tissue damage or injury |
| 02/25/2003 | US6525040 4,4-dimethyl-thieno-(3,2-e)-isoselenazine; antioxidants and cytoprotecting |
| 02/25/2003 | US6525039 B-ring estratrienes |
| 02/25/2003 | US6525038 Synergistic compositions for the selective control of tumor tissue |
| 02/25/2003 | US6525037 Method of treating atherosclerosis and complications resulting therefrom |
| 02/25/2003 | US6525036 Compounds and compositions as protease inhibitors |
| 02/25/2003 | US6525035 Therapeutic composition and methods |
| 02/25/2003 | US6525033 2', 3' dideoxynucleoside compounds; 2',3'-dideoxycytidine (beta -L-FddC), beta -L-2',3'-dideoxy-5-fluorocytidine (beta-L-ddC); beta-D-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-dioxolane |
| 02/25/2003 | US6525027 For use in human performing weight-training exercise |
| 02/25/2003 | US6525026 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 02/25/2003 | US6525020 For drug delivery |
| 02/25/2003 | US6525019 Use of melanin for inhibition of angiogenesis and macular degeneration |
| 02/25/2003 | US6524832 Treating the cells with a therapeutically effective amount of ionizing radiation or alkylating agent as DNA damaging agent; contacting the cells with a protein tyrosine kinase inhibitor such as genistein or herbimycin A |
| 02/25/2003 | US6524813 Novel polynucleotides and polypeptides of the spo0J family derived from Staphylococcus |
| 02/25/2003 | US6524806 Methods of screening for ligands of human hemetopoietin receptor HU-B1.219 |
| 02/25/2003 | US6524805 Cell expressing said receptors contacted with test compound; if induced response is inhibited by tamoxifen, but not by internal estrogen receptor antagonist then test compound is an agonist |
| 02/25/2003 | US6524802 Methods of detecting growth differentiation factor-14 |
| 02/25/2003 | US6524788 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| 02/25/2003 | US6524630 Use of cocoa procyanidins combined with acelylsalicyclic acid as an anti-platelet therapy |
| 02/25/2003 | US6524629 20-30% of flavoneglycosides, 2.5-4.5% of ginkgolides A, B, C, and J, 2-4% of biloblaide, < 10% proanthocyanidines, < 10 ppm of an alkylphenol and ginkobiloba extract |
| 02/25/2003 | US6524628 Exposing a ginko sample to a pressurized liquid aqueous composition at a temperature of 0-100 degrees c and pressure of 50-1000 atm, and isolating solubilized material |
| 02/25/2003 | US6524625 Physiologically active extract obtained from indigo plant polygonum tinctorium |
| 02/25/2003 | US6524623 Therapeutic compositions and methods of use thereof |
| 02/25/2003 | US6524620 Diltiazem controlled release formulation and method of manufacture |
| 02/25/2003 | US6524619 Interdependent biofactors and biomolecules, such as minerals, vitamins and antioxidants and their clinically useful formulations for support of endothelial physiology of the inner ear |
| 02/25/2003 | US6524616 Compositions and methods for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with alzheimer's disease, aging, other dementia related disorders and estrogen deficiency related conditions |
| 02/25/2003 | US6524613 Hepatocellular chimeraplasty |
| 02/25/2003 | US6524612 Adhesive cooling composition and process for its preparation |
| 02/25/2003 | US6524611 The latter for stability in aqueous medium, for human consumption |
| 02/25/2003 | US6524610 Nutritional composition made from conventional foods for mixing onsite in a blender and treating patients with hepatic disorders |
| 02/25/2003 | US6524608 Intravesical drug delivery system |
| 02/25/2003 | US6524607 Nontoxic, nonglucocorticoid, biocompatible, biodegradable, controlled release material |
| 02/25/2003 | US6524599 Use of milk thistle extract in skin care compositions |
| 02/25/2003 | US6524593 N-acetyl aldosamines and related N-acetyl compounds, and their topical use |
| 02/25/2003 | US6524569 Anionic-cationic polyion complexes comprising zwitterionic monomer component |
| 02/25/2003 | US6524567 Synthetic soil-extract materials and medicaments for hemorrhagic fever viruses based thereon |
| 02/25/2003 | US6524566 Synthetic soil-extract materials and medicaments for herpes viruses based thereon |
| 02/25/2003 | US6524556 Tricyclic compound dispersed in liquefied hydrofluoroalkane propellant; medium-chain fatty acid triglyceride as dispersant |
| 02/25/2003 | US6524527 Conjugated linoleic acid compositions |
| 02/25/2003 | US6524347 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| 02/25/2003 | CA2420556A1 Infusion of ciprofloxacin having reduced acid content and being stable on storage |
| 02/25/2003 | CA2238331C Cancerous metastasis inhibitors containing uracil derivatives |
| 02/25/2003 | CA2231192C Pharmaceutical combination preparations containing erythropoietin and iron preparations |
| 02/25/2003 | CA2171852C Budesonide pellets with a controlled release pattern and process for producing them |
| 02/25/2003 | CA2113080C Topical composition containing penciclovir |
| 02/25/2003 | CA2104868C Method and products for treating the eye |
| 02/25/2003 | CA2085525C Long lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |